Thrombocytopenia in MDS

Epidemiology, mechanisms, clinical consequences and novel therapeutic strategies

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Thrombocytopenia is commonly seen in myelodysplastic syndrome (MDS) patients, and bleeding complications are a major cause of morbidity and mortality. Thrombocytopenia is an independent factor for decreased survival and has been incorporated in newer prognostic scoring systems. The mechanisms of thrombocytopenia are multifactorial and involve a differentiation block of megakaryocytic progenitor cells, leading to dysplastic, hypolobated and microscopic appearing megakaryocytes or increased apoptosis of megakaryocytes and their precursors. Dysregulated thrombopoietin (TPO) signaling and increased platelet destruction through immune or nonimmune mechanisms are frequently observed in MDS. The clinical management of patients with low platelet counts remains challenging and approved chemotherapeutic agents such as lenalidomide and azacytidine can also lead to a transient worsening of thrombocytopenia. Platelet transfusion is the only supportive treatment option currently available for clinically significant thrombocytopenia. The TPO receptor agonists romiplostim and eltrombopag have shown clinical activity in clinical trials in MDS. In addition to thrombopoietic effects, eltrombopag can inhibit leukemic cell proliferation via TPO receptor-independent effects. Other approaches such as treatment with cytokines, immunomodulating drugs and signal transduction inhibitors have shown limited activity in selected groups of MDS patients. Combination trials of approved agents with TPO agonists are ongoing and hold promise for this important clinical problem.

Original languageEnglish (US)
Pages (from-to)536-544
Number of pages9
JournalLeukemia
Volume30
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Myelodysplastic Syndromes
Thrombocytopenia
Epidemiology
Thrombopoietin Receptors
Thrombopoietin
Megakaryocytes
Therapeutics
Azacitidine
Platelet Transfusion
Platelet Count
Signal Transduction
Stem Cells
Blood Platelets
Cell Proliferation
Clinical Trials
Apoptosis
Hemorrhage
Cytokines
Morbidity
Survival

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Thrombocytopenia in MDS : Epidemiology, mechanisms, clinical consequences and novel therapeutic strategies. / Li, W.; Morrone, Kerry A.; Kambhampati, S.; Will, Britta; Steidl, Ulrich G.; Verma, Amit K.

In: Leukemia, Vol. 30, No. 3, 01.03.2016, p. 536-544.

Research output: Contribution to journalArticle

@article{c6ff544fdee54754ad367c9d476ee946,
title = "Thrombocytopenia in MDS: Epidemiology, mechanisms, clinical consequences and novel therapeutic strategies",
abstract = "Thrombocytopenia is commonly seen in myelodysplastic syndrome (MDS) patients, and bleeding complications are a major cause of morbidity and mortality. Thrombocytopenia is an independent factor for decreased survival and has been incorporated in newer prognostic scoring systems. The mechanisms of thrombocytopenia are multifactorial and involve a differentiation block of megakaryocytic progenitor cells, leading to dysplastic, hypolobated and microscopic appearing megakaryocytes or increased apoptosis of megakaryocytes and their precursors. Dysregulated thrombopoietin (TPO) signaling and increased platelet destruction through immune or nonimmune mechanisms are frequently observed in MDS. The clinical management of patients with low platelet counts remains challenging and approved chemotherapeutic agents such as lenalidomide and azacytidine can also lead to a transient worsening of thrombocytopenia. Platelet transfusion is the only supportive treatment option currently available for clinically significant thrombocytopenia. The TPO receptor agonists romiplostim and eltrombopag have shown clinical activity in clinical trials in MDS. In addition to thrombopoietic effects, eltrombopag can inhibit leukemic cell proliferation via TPO receptor-independent effects. Other approaches such as treatment with cytokines, immunomodulating drugs and signal transduction inhibitors have shown limited activity in selected groups of MDS patients. Combination trials of approved agents with TPO agonists are ongoing and hold promise for this important clinical problem.",
author = "W. Li and Morrone, {Kerry A.} and S. Kambhampati and Britta Will and Steidl, {Ulrich G.} and Verma, {Amit K.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1038/leu.2015.297",
language = "English (US)",
volume = "30",
pages = "536--544",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Thrombocytopenia in MDS

T2 - Epidemiology, mechanisms, clinical consequences and novel therapeutic strategies

AU - Li, W.

AU - Morrone, Kerry A.

AU - Kambhampati, S.

AU - Will, Britta

AU - Steidl, Ulrich G.

AU - Verma, Amit K.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Thrombocytopenia is commonly seen in myelodysplastic syndrome (MDS) patients, and bleeding complications are a major cause of morbidity and mortality. Thrombocytopenia is an independent factor for decreased survival and has been incorporated in newer prognostic scoring systems. The mechanisms of thrombocytopenia are multifactorial and involve a differentiation block of megakaryocytic progenitor cells, leading to dysplastic, hypolobated and microscopic appearing megakaryocytes or increased apoptosis of megakaryocytes and their precursors. Dysregulated thrombopoietin (TPO) signaling and increased platelet destruction through immune or nonimmune mechanisms are frequently observed in MDS. The clinical management of patients with low platelet counts remains challenging and approved chemotherapeutic agents such as lenalidomide and azacytidine can also lead to a transient worsening of thrombocytopenia. Platelet transfusion is the only supportive treatment option currently available for clinically significant thrombocytopenia. The TPO receptor agonists romiplostim and eltrombopag have shown clinical activity in clinical trials in MDS. In addition to thrombopoietic effects, eltrombopag can inhibit leukemic cell proliferation via TPO receptor-independent effects. Other approaches such as treatment with cytokines, immunomodulating drugs and signal transduction inhibitors have shown limited activity in selected groups of MDS patients. Combination trials of approved agents with TPO agonists are ongoing and hold promise for this important clinical problem.

AB - Thrombocytopenia is commonly seen in myelodysplastic syndrome (MDS) patients, and bleeding complications are a major cause of morbidity and mortality. Thrombocytopenia is an independent factor for decreased survival and has been incorporated in newer prognostic scoring systems. The mechanisms of thrombocytopenia are multifactorial and involve a differentiation block of megakaryocytic progenitor cells, leading to dysplastic, hypolobated and microscopic appearing megakaryocytes or increased apoptosis of megakaryocytes and their precursors. Dysregulated thrombopoietin (TPO) signaling and increased platelet destruction through immune or nonimmune mechanisms are frequently observed in MDS. The clinical management of patients with low platelet counts remains challenging and approved chemotherapeutic agents such as lenalidomide and azacytidine can also lead to a transient worsening of thrombocytopenia. Platelet transfusion is the only supportive treatment option currently available for clinically significant thrombocytopenia. The TPO receptor agonists romiplostim and eltrombopag have shown clinical activity in clinical trials in MDS. In addition to thrombopoietic effects, eltrombopag can inhibit leukemic cell proliferation via TPO receptor-independent effects. Other approaches such as treatment with cytokines, immunomodulating drugs and signal transduction inhibitors have shown limited activity in selected groups of MDS patients. Combination trials of approved agents with TPO agonists are ongoing and hold promise for this important clinical problem.

UR - http://www.scopus.com/inward/record.url?scp=84959337233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959337233&partnerID=8YFLogxK

U2 - 10.1038/leu.2015.297

DO - 10.1038/leu.2015.297

M3 - Article

VL - 30

SP - 536

EP - 544

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -